HC Wainwright & Co. Maintains 'Buy' Rating for Praxis Precision Medicine with $105 Target

HC Wainwright & Co. has maintained its 'Buy' rating for Praxis Precision Medicine (PRAX) with a price target of $105. The firm's confidence in PRAX's growth prospects and valuation in the current market environment is reflected in the consistent rating. The average target price for PRAX is $99.17, with a high estimate of $270.00 and a low estimate of $28.00, indicating an upside of 80.50% from the current price of $54.94.

HC Wainwright & Co. has maintained its 'Buy' rating for Praxis Precision Medicines (PRAX), with a price target of $105. This reaffirmation underscores the firm's confidence in PRAX's growth prospects and valuation in the current market environment. The average target price for PRAX is $99.17, with a high estimate of $270.00 and a low estimate of $28.00, indicating an upside of 80.50% from the current price of $54.94.

The latest update from HC Wainwright comes amid a flurry of analyst activity surrounding PRAX. Several other analysts have also issued reports, with Needham & Company LLC reaffirming a 'buy' rating and setting a $80.00 target price [1]. Wedbush increased their target price to $28.00 and gave the company an 'underperform' rating [2]. Oppenheimer lifted their target price to $115.00 and gave the stock an 'outperform' rating [3]. Chardan Capital began coverage with a 'buy' rating and a $80.00 price target [4].

Praxis Precision Medicines' stock has seen mixed reactions, trading down $1.09 on Friday, July 18, 2025, to hit $53.85. The company's 52-week low is $26.70 and its 52-week high is $91.83. The firm has a market cap of $1.10 billion, a P/E ratio of -5.02, and a beta of 2.60.

Institutional investors have shown interest in PRAX, with several increasing their stakes. Cormorant Asset Management LP grew its position by 3.1% in the first quarter [5]. Adage Capital Partners GP L.L.C. increased its position by 188.1% [6]. Price T Rowe Associates Inc. MD lifted its position by 7.9% during the fourth quarter [7]. Vanguard Group Inc. increased its position by 2.2% in the first quarter [8]. VR Adviser LLC boosted its stake by 40.2% during the fourth quarter [9].

Praxis Precision Medicines is a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. Its pipeline includes ulixacaltamide, a small molecule inhibitor of T-type calcium channels in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.

References:
[1] https://www.marketbeat.com/instant-alerts/praxis-precision-medicines-nasdaqprax-earns-buy-rating-from-hc-wainwright-2025-07-18/
[2] https://www.ainvest.com/news/angiodynamics-hc-wainwright-raises-buy-rating-pt-boosted-16-2507/
[3] https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/were-hopeful-that-praxis-precision-medicines-nasdaqprax-will-2